Plain-English translation of NCT07221097 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are evaluating the accuracy of the BioFire Emerging Coronavirus Panel, a test that detects COVID-19 and other coronaviruses in respiratory samples. This study uses leftover samples from routine respiratory infection testing that would normally be discarded, so participants don't need to provide anything extra. The goal is to see how well this new test identifies coronaviruses compared to other standard detection methods.
As new coronavirus variants continue to emerge, doctors need reliable, fast tests to identify infections in people with respiratory symptoms. This study will help confirm whether the BioFire test is accurate enough to use in real clinical settings to help patients get diagnosed and treated quickly.
You likely qualify if…
You likely don't qualify if…
You don't need to do anything special—this study uses samples that are already collected as part of your regular respiratory infection testing. After your doctor's routine test is complete, any leftover sample is used for this research study. There are no additional appointments, procedures, or follow-up required from you.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States